Replies to post #248032 on Amarin Corp Plc (AMRN)

[MontanaState83]

All predicated on winning the BS litigation. A trial whose outcome hinges on which side of the bed Du gets out on. Seriously, it could go south due to the lack of a parenthetical reference. With billions at stake, the total subjectivity of the litigation is beyond ridiculous

[couldbebetter]

What may be key to beyond August, 2029 would be the adoption by AMRN
of a "one a day" version of Vascepa, most likely being developed by
AMRN's partner Mochida. Certainly, I wonder how such a capsule would
look and how much larger it may be in comparison to the 1 gram Vascepa
capsule we have today. Doctors would prefer a one a day version so
as to increase compliance.

With regard to the prospect of a takeout I cannot see how BP could
ignore Vascepa. Certainly, BP would model out what they could do
with Vascepa using their own massive marketing and distribution muscle.
(Especially with regard to Europe.) JT's mention of a possible GIA
in Europe seems absurd. On the one hand JT claims great interest in
Vascepa for Europe, so why the GIA talk? Is that JT's way of saying
he will GIA unless or until the right (BO?) (Partnership?) deal comes
along?